1199: Canadian Urologic Oncology Group (CUOG) Phase II Study Using Docetaxel/Prednisone in the Second Line Setting for Metastatic Androgen Independent Prostate Cancer in Patients Progressing after First Line Mitoxantrone/Prednisone
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.